FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1973544363> ?p ?o ?g. }

• W1973544363 endingPage "869" @default.
• W1973544363 startingPage "863" @default.
• W1973544363 abstract "Purpose To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). Methods and Materials This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. Results The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Conclusions Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed. To investigate long-term disease and toxicity outcomes for pediatric retinoblastoma patients treated with proton radiation therapy (PRT). This is a retrospective analysis of 49 retinoblastoma patients (60 eyes) treated with PRT between 1986 and 2012. The majority (84%) of patients had bilateral disease, and nearly half (45%) had received prior chemotherapy. At a median follow-up of 8 years (range, 1-24 years), no patients died of retinoblastoma or developed metastatic disease. The post-PRT enucleation rate was low (18%), especially in patients with early-stage disease (11% for patients with International Classification for Intraocular Retinoblastoma [ICIR] stage A-B disease vs 23% for patients with ICIR stage C-D disease). Post-PRT ophthalmologic follow-up was available for 61% of the preserved eyes (30 of 49): 14 of 30 eyes (47%) had 20/40 visual acuity or better, 7 of 30 (23%) had moderate visual acuity (20/40-20/600), and 9 of 30 (30%) had little or no useful vision (worse than 20/600). Twelve of 60 treated eyes (20%) experienced a post-PRT event requiring intervention, with cataracts the most common (4 eyes). No patients developed an in-field second malignancy. Long-term follow-up of retinoblastoma patients treated with PRT demonstrates that PRT can achieve high local control rates, even in advanced cases, and many patients retain useful vision in the treated eye. Treatment-related ocular side effects were uncommon, and no radiation-associated malignancies were observed." @default.
• W1973544363 created "2016-06-24" @default.
• W1973544363 creator A5014884181 @default.
• W1973544363 creator A5016095152 @default.
• W1973544363 creator A5017933458 @default.
• W1973544363 creator A5032331306 @default.
• W1973544363 creator A5045425111 @default.
• W1973544363 creator A5056658906 @default.
• W1973544363 creator A5066592938 @default.
• W1973544363 creator A5069517897 @default.
• W1973544363 creator A5070676019 @default.
• W1973544363 creator A5071690284 @default.
• W1973544363 creator A5072375420 @default.
• W1973544363 creator A5073123534 @default.
• W1973544363 date "2014-11-01" @default.
• W1973544363 modified "2023-09-27" @default.
• W1973544363 title "Proton Radiation Therapy for the Treatment of Retinoblastoma" @default.
• W1973544363 cites W1496390158 @default.
• W1973544363 cites W1844379777 @default.
• W1973544363 cites W1857598851 @default.
• W1973544363 cites W1978465109 @default.
• W1973544363 cites W1983790283 @default.
• W1973544363 cites W1983805637 @default.
• W1973544363 cites W1988505823 @default.
• W1973544363 cites W2050617043 @default.
• W1973544363 cites W2057990213 @default.
• W1973544363 cites W2071531151 @default.
• W1973544363 cites W2074538055 @default.
• W1973544363 cites W2081541249 @default.
• W1973544363 cites W2091317615 @default.
• W1973544363 cites W2124966703 @default.
• W1973544363 cites W2125439178 @default.
• W1973544363 cites W2136770973 @default.
• W1973544363 cites W2155415371 @default.
• W1973544363 cites W4254892493 @default.
• W1973544363 doi "https://doi.org/10.1016/j.ijrobp.2014.07.031" @default.
• W1973544363 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4253018" @default.
• W1973544363 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25227498" @default.
• W1973544363 hasPublicationYear "2014" @default.
• W1973544363 type Work @default.
• W1973544363 sameAs 1973544363 @default.
• W1973544363 citedByCount "41" @default.
• W1973544363 countsByYear W19735443632015 @default.
• W1973544363 countsByYear W19735443632016 @default.
• W1973544363 countsByYear W19735443632017 @default.
• W1973544363 countsByYear W19735443632018 @default.
• W1973544363 countsByYear W19735443632019 @default.
• W1973544363 countsByYear W19735443632020 @default.
• W1973544363 countsByYear W19735443632021 @default.
• W1973544363 countsByYear W19735443632022 @default.
• W1973544363 crossrefType "journal-article" @default.
• W1973544363 hasAuthorship W1973544363A5014884181 @default.
• W1973544363 hasAuthorship W1973544363A5016095152 @default.
• W1973544363 hasAuthorship W1973544363A5017933458 @default.
• W1973544363 hasAuthorship W1973544363A5032331306 @default.
• W1973544363 hasAuthorship W1973544363A5045425111 @default.
• W1973544363 hasAuthorship W1973544363A5056658906 @default.
• W1973544363 hasAuthorship W1973544363A5066592938 @default.
• W1973544363 hasAuthorship W1973544363A5069517897 @default.
• W1973544363 hasAuthorship W1973544363A5070676019 @default.
• W1973544363 hasAuthorship W1973544363A5071690284 @default.
• W1973544363 hasAuthorship W1973544363A5072375420 @default.
• W1973544363 hasAuthorship W1973544363A5073123534 @default.
• W1973544363 hasBestOaLocation W19735443632 @default.
• W1973544363 hasConcept C104317684 @default.
• W1973544363 hasConcept C118487528 @default.
• W1973544363 hasConcept C126322002 @default.
• W1973544363 hasConcept C141071460 @default.
• W1973544363 hasConcept C146357865 @default.
• W1973544363 hasConcept C151730666 @default.
• W1973544363 hasConcept C167135981 @default.
• W1973544363 hasConcept C185592680 @default.
• W1973544363 hasConcept C188261085 @default.
• W1973544363 hasConcept C2776148792 @default.
• W1973544363 hasConcept C2776577112 @default.
• W1973544363 hasConcept C2778257484 @default.
• W1973544363 hasConcept C2779134260 @default.
• W1973544363 hasConcept C2779399171 @default.
• W1973544363 hasConcept C2780225610 @default.
• W1973544363 hasConcept C509974204 @default.
• W1973544363 hasConcept C55493867 @default.
• W1973544363 hasConcept C71924100 @default.
• W1973544363 hasConcept C86803240 @default.
• W1973544363 hasConceptScore W1973544363C104317684 @default.
• W1973544363 hasConceptScore W1973544363C118487528 @default.
• W1973544363 hasConceptScore W1973544363C126322002 @default.
• W1973544363 hasConceptScore W1973544363C141071460 @default.
• W1973544363 hasConceptScore W1973544363C146357865 @default.
• W1973544363 hasConceptScore W1973544363C151730666 @default.
• W1973544363 hasConceptScore W1973544363C167135981 @default.
• W1973544363 hasConceptScore W1973544363C185592680 @default.
• W1973544363 hasConceptScore W1973544363C188261085 @default.
• W1973544363 hasConceptScore W1973544363C2776148792 @default.
• W1973544363 hasConceptScore W1973544363C2776577112 @default.
• W1973544363 hasConceptScore W1973544363C2778257484 @default.
• W1973544363 hasConceptScore W1973544363C2779134260 @default.
• W1973544363 hasConceptScore W1973544363C2779399171 @default.
• W1973544363 hasConceptScore W1973544363C2780225610 @default.

• next